U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15N7O2S3.ClH
Molecular Weight 373.906
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FAMOTIDINE HYDROCHLORIDE

SMILES

Cl.NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1

InChI

InChIKey=OONJNILIBCMSNC-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3.ClH/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11;/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14);1H

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/famotidine.html

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.

Originator

Approval Year

1986
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 0.3 µM [IC50]
Inhibitor
8504
 6.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Primary
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
424 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg 2 times / day steady, oral
Recommended
Dose: 0.5 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 11 - 15 years
Health Status: unhealthy
Age Group: 11 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Other AEs: Dizziness, Dry skin...
Other AEs:
Dizziness (grade 1, 2 patients)
Dry skin (grade 1, 1 patient)
Insomnia (grade 1, 1 patient)
Gastrointestinal disorder (NOS) (grade 1, 1 patient)
Forgetfulness (grade 1, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
1 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 1 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 6 - 15 years
Health Status: unhealthy
Age Group: 6 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2 patients)
Nausea (6 patients)
Dyspepsia (5 patients)
Diarrhea (5 patients)
Constipation (4 patients)
Abdominal pain upper (3 patients)
Gastroesophageal reflux disease (2 patients)
Vomiting (2 patients)
Stomach discomfort (2 patients)
Abdominal pain (2 patients)
Edema peripheral (2 patients)
Arthralgia (1 patient)
Back pain (2 patients)
Headache (3 patients)
Hypertension (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
AEs

AEs

AESignificanceDosePopulation
Dry skin grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Forgetfulness grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Gastrointestinal disorder (NOS) grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Insomnia grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Dizziness grade 1, 2 patients
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Arthralgia 1 patient
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Anemia 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Back pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Edema peripheral 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Gastroesophageal reflux disease 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Stomach discomfort 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Vomiting 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain upper 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Headache 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Hypertension 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Constipation 4 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Diarrhea 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Dyspepsia 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Nausea 6 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2B6
926

CYP2C19
2057

OCT1
620

OCT2
779

OCT3
159

MATE1
415

MATE2
267
OCT2
434
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 weak
likely (co-administration study)
Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value
Page: 6.0
OCT2
782
 yes [IC50 114 uM]
OCT1
656
 yes [IC50 28 uM]
OCT3
161
 yes [IC50 6.7 uM]
CYP2B6
1160
 yes [Inhibition 100 uM]
CYP2C19
2141
 yes [Inhibition 100 uM]
CYP3A4
2633
 yes [Inhibition 100 uM]
MATE1
416
 yes [Ki 0.6 uM]
MATE2
267
 yes [Ki 9.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OCT2
434
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4975
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4975
ChemicalBook
CB5706585
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5706585
eMolecules
538460
https://www.emolecules.com/cgi-bin/more?vid=538460
eMolecules
6842898
https://www.emolecules.com/cgi-bin/more?vid=6842898
eMolecules
901873
https://www.emolecules.com/cgi-bin/more?vid=901873
MolPort
MolPort-002-557-620
https://www.molport.com/shop/molecule-link/MolPort-002-557-620
MolPort
MolPort-003-666-342
https://www.molport.com/shop/molecule-link/MolPort-003-666-342
MolPort
MolPort-003-941-395
https://www.molport.com/shop/molecule-link/MolPort-003-941-395
MolPort
MolPort-006-069-255
https://www.molport.com/shop/molecule-link/MolPort-006-069-255
Selleck Chemicals
famotidine-pepcid
http://www.selleckchem.com/products/famotidine-pepcid.html
ZINC
ZINC000001530636
http://zinc15.docking.org/substances/ZINC000001530636
PubMed

PubMed

TitleDatePubMed
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011-02
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
2010-07-30
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
2010-04
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
2010-04
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
2010-01
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.
2009-12
[Neurological complications of acute intermittent porphyria precipitated by porphyrinogenic drugs and efficiency of heme-arginate treatment].
2009-09
Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters.
2009-09
Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats.
2009-07-15
Antinociception induced by central administration of histamine in the formalin test in rats.
2009-06-26
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
2009-06
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment.
2009-06
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
2009-04
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
2009-03
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
2009-02
Hepatitis following famotidine: a case report.
2009-01-27
Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study.
2009
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis.
2009
Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor.
2009
Effects of mepyramine and famotidine on the physostigmine-induced antinociception in the formalin test in rats.
2008-11-15
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
2008-10
[Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
2008-10
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?
2008-08
Nonsurgical resolution of gallbladder mucocele in two dogs.
2008-06-01
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
2008-02
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats.
2008
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
2008
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.
2007-11
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.
2007-10
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
2007-09
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.
2007-07-15
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer].
2007-07
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
2007-01
Histamine stimulation of MMP-1(collagenase-1) secretion and gene expression in gastric epithelial cells: role of EGFR transactivation and the MAP kinase pathway.
2007
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
2006-12
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection.
2006-10-20
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
2006-10-03
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
2006-10
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
2006-10
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.
2006-09-01
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach.
2006-08
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.
2006-08
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.
2006-05
Effect of preoperative short course famotidine on TILs and survival in breast cancer.
2006-01-05
In vitro availability of metformin in presence of h(2) receptor antagonists.
2006-01
[Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease].
2006
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.
2005-12-07
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
2005
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
2005
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
1991-04
Patents

Patents

05021582
2
JP2000197427A
2
JP2000219625A
2
JP2000302679A
2
JP2001302510A
2
JP2002017866A
2
JP2002087958A
2
JP2002145776A
2
JP2002291901A
2
JP2002322057A
2
JP2002511777A
420
JP2002537317A
97
JP2002538104A
9
JP2003088495A
2
JP2003095946A
2
JP2003206229A
2
JP2003212772A
2
JP2003261449A
2
JP2003275318A
2
JP2003275324A
2
JP2003275325A
2
JP2003284722A
2
JP2003305122A
2
JP2003515553A
3
JP2004223027A
2
JP2004261566A
2
JP2005168980A
2
JP2006089393A
2
JP2006273819A
2
JP2007008845A
5
JP2007055905A
2
JP2007284453A
2
JP2007507425A
18
JP2007518689A
11
JP2007525670A
150
JP2008504040A
2
JP2009526755A
475
JP2010088502A
2
JP2011079841A
5
JP2011223965A
2
JP2011229496A
2
JP2011525178A
25
JP2011528275A
456
JP4664289B2
2
JP4722295B2
105
JP4732696B2
68
JP4739217B2
51
JP4756823B2
22
JP4763957B2
87
JP4787165B2
104
JPH01100162A
2
JPH01197439A
2

Sample Use Guides

In Vivo Use Guide
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Name Type Language
FAMOTIDINE HCL
Preferred Name English
FAMOTIDINE HYDROCHLORIDE
Common Name English
PROPANIMIDAMIDE, 3-(((2-((AMINOIMINOMETHYL)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-(AMINOSULFONYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
PROPANIMIDAMIDE, 3-(((2-((AMINOIMINOMETHYL)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-(AMINOSULFONYL)-, HYDROCHLORIDE
Systematic Name English
PROPANIMIDAMIDE, 3-(((2-((AMINOIMINOMETHYL)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-(AMINOSULFONYL)-, MONOHYDROCHLORIDE
Systematic Name English
Code System Code Type Description
PUBCHEM
19831515
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID20910894
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
HSDB
108885-67-2
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
SMS_ID
300000047375
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
CHEBI
50377
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
FDA UNII
36YPT1XMT2
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
CAS
108885-67-2
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
NON-SPECIFIC STOICHIOMETRY
CAS
125193-62-6
Created by admin on Mon Mar 31 22:50:33 GMT 2025 , Edited by admin on Mon Mar 31 22:50:33 GMT 2025
PRIMARY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966